Trial: 202003013

A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti-PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC)

Phase

I/II

Principal Investigator

Pachynski, Russell

Disease Site

Kidney

Learn more about this study at: clinicaltrials.gov